Aerie Pharmaceuticals Inc
NASDAQ:AERI
Aerie Pharmaceuticals Inc
Operating Income
Aerie Pharmaceuticals Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Aerie Pharmaceuticals Inc
NASDAQ:AERI
|
Operating Income
-$26.7m
|
CAGR 3-Years
48%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Aerie Pharmaceuticals Inc's Operating Income?
Operating Income
-26.7m
USD
Based on the financial report for Sep 30, 2022, Aerie Pharmaceuticals Inc's Operating Income amounts to -26.7m USD.
What is Aerie Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
25%
Over the last year, the Operating Income growth was 80%. The average annual Operating Income growth rates for Aerie Pharmaceuticals Inc have been 48% over the past three years , 25% over the past five years .